^
BIOMARKER:

BRAF mutation

i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
BRAF mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF mutation
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive
:
C3
ISPOR-EU 2022 - 4 weeks - (New C3)
BRAF mutation
Melanoma
dabrafenib + granisetron intravenous
Sensitive
:
A2
BRAF mutation
Colorectal Cancer
ramucirumab
Sensitive
:
B
BRAF mutation
Colorectal Cancer
ziv-aflibercept IV
Sensitive
:
B
BRAF mutation
Colorectal Cancer
bevacizumab
Sensitive
:
B
BRAF mutation
Colorectal Cancer
cetuximab
Resistant
:
B
BRAF mutation
Colorectal Cancer
regorafenib
Sensitive
:
B
BRAF mutation
Melanoma
nivolumab + ipilimumab
Sensitive
:
B
BRAF mutation
Colorectal Cancer
FOLFIRI + cetuximab
Sensitive
:
B
BRAF mutation
Acute Myelogenous Leukemia
gilteritinib
Resistant
:
B
BRAF mutation
Melanoma
PD-L1 inhibitor
Sensitive
:
B
BRAF mutation
Melanoma
ipilimumab
Sensitive
:
B
BRAF mutation
Colorectal Cancer
panitumumab
Sensitive
:
C2
BRAF mutation
Melanoma
encorafenib + binimetinib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Carcinoma
selumetinib
Sensitive
:
C2
BRAF mutation
Melanoma
BVD-523
Sensitive
:
C2
BRAF mutation
Melanoma
trametinib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive
:
C2
BRAF mutation
Colon Cancer
bevacizumab
Sensitive
:
C2
BRAF mutation
Melanoma
selumetinib
Sensitive
:
C2
BRAF mutation
Pancreatic Cancer
vemurafenib
Sensitive
:
C2
BRAF mutation
Non Small Cell Lung Cancer
durvalumab
Resistant
:
C2
BRAF mutation
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive
:
C2
BRAF mutation
Melanoma
nivolumab
Sensitive
:
C2
BRAF mutation
Rectal Cancer
bevacizumab
Sensitive
:
C2
BRAF mutation
Melanoma
pembrolizumab
Sensitive
:
C2
BRAF mutation
Colorectal Cancer
nivolumab + bevacizumab
Sensitive
:
C2
BRAF mutation
Melanoma
vemurafenib + cobimetinib
Sensitive
:
C2
BRAF mutation
Melanoma
cobimetinib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
vemurafenib
Sensitive
:
C2
BRAF mutation
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive
:
C3
BRAF mutation
Non Small Cell Lung Cancer
PD1 inhibitor
Sensitive
:
C3
BRAF mutation
Melanoma
Immunotherapy
Resistant
:
C3